Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist
暂无分享,去创建一个
[1] H. S. Warren,et al. Toll-like receptors. , 2005, Critical care medicine.
[2] Stephanie B. Conant,et al. Autoreactive T Cells Persist in Rats Protected against Experimental Autoimmune Encephalomyelitis and Can Be Activated through Stimulation of Innate Immunity1 , 2004, The Journal of Immunology.
[3] D. Pardoll,et al. Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.
[4] D. Klinman. Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.
[5] V. Hornung,et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. , 2004, Blood.
[6] S. Akira,et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.
[7] R. DeMatteo,et al. Liver Dendritic Cells Are Less Immunogenic Than Spleen Dendritic Cells because of Differences in Subtype Composition1 , 2004, The Journal of Immunology.
[8] B. Monks,et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome , 2004, Nature Immunology.
[9] P. Payette,et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities , 2004, European journal of immunology.
[10] T. Utsugi,et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. , 2003, Immunity.
[11] M. Shlomchik,et al. Activation of autoreactive B cells by CpG dsDNA. , 2003, Immunity.
[12] J. Sprent,et al. T cell memory. , 2003, Annual review of immunology.
[13] I. Kerr,et al. Differential Responses to IFN-α Subtypes in Human T Cells and Dendritic Cells 12 , 2003, The Journal of Immunology.
[14] R. Koup,et al. Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses 1 , 2003, The Journal of Immunology.
[15] I. Astsaturov,et al. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] P. Borrow,et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon , 2003, Nature Immunology.
[17] Mary K. Crow. Interferon-α: A new target for therapy in systemic lupus erythematosus? , 2003 .
[18] S. Halperin,et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. , 2003, Vaccine.
[19] A. Lanzavecchia,et al. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. , 2003, Blood.
[20] G. Hartmann,et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN‐α induction in plasmacytoid dendritic cells , 2003, European journal of immunology.
[21] R. Coffman,et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions , 2003, Journal of leukocyte biology.
[22] A. Krieg,et al. CpG-A-Induced Monocyte IFN-γ-Inducible Protein-10 Production Is Regulated by Plasmacytoid Dendritic Cell-Derived IFN-α1 , 2003, The Journal of Immunology.
[23] E. Uhlmann,et al. Recent advances in the development of immunostimulatory oligonucleotides. , 2003, Current opinion in drug discovery & development.
[24] G. Karypis,et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] Ruslan Medzhitov,et al. Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.
[26] Jae-Geun Yoon,et al. CpG DNA Induces Self and Cross-Hyporesponsiveness of RAW264.7 Cells in Response to CpG DNA and Lipopolysaccharide: Alterations in IL-1 Receptor-Associated Kinase Expression1 , 2003, The Journal of Immunology.
[27] A. Krieg. CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both? , 2003, Scandinavian journal of infectious diseases.
[28] Antonio Lanzavecchia,et al. Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells , 2002, Science.
[29] Y. Choi,et al. Distinct Response of Human B Cell Subpopulations in Recognition of an Innate Immune Signal, CpG DNA , 2002, The Journal of Immunology.
[30] R. Vabulas,et al. Bacterial CpG‐DNA and lipopolysaccharides activate Toll‐like receptors at distinct cellular compartments , 2002, European journal of immunology.
[31] K. Heeg,et al. Immunostimulatory CpG-DNA Activates Murine Microglia1 , 2002, The Journal of Immunology.
[32] T. Giese,et al. Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides1 , 2002, The Journal of Immunology.
[33] M. Shlomchik,et al. Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.
[34] L. Rönnblom,et al. A Pivotal Role for the Natural Interferon α–producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus , 2001, The Journal of experimental medicine.
[35] L. Rönnblom,et al. A Pivotal Role for the Natural Interferon α–producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus , 2001 .
[36] Virginia Pascual,et al. Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus , 2001, Science.
[37] L. Babiuk,et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. , 2001, Antisense & nucleic acid drug development.
[38] N. Kadowaki,et al. Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.
[39] T. Giese,et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. , 2001, European journal of immunology.
[40] S. Akira,et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] V. Hornung,et al. Identification of CpG oligonucleotide sequences with high induction of IFN‐α/β in plasmacytoid dendritic cells , 2001 .
[42] G. Gaedicke,et al. IFN-γ-Inducible Protein-10 Is Essential for the Generation of a Protective Tumor-Specific CD8 T Cell Response Induced by Single-Chain IL-12 Gene Therapy1 , 2001, The Journal of Immunology.
[43] S. Yousefi,et al. Cloning and expression analysis of a novel G‐protein‐coupled receptor selectively expressed on granulocytes , 2001, Journal of leukocyte biology.
[44] K. Ishii,et al. Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs1 2 , 2001, The Journal of Immunology.
[45] N. Kadowaki,et al. Distinct CpG DNA and Polyinosinic-Polycytidylic Acid Double-Stranded RNA, Respectively, Stimulate CD11c− Type 2 Dendritic Cell Precursors and CD11c+ Dendritic Cells to Produce Type I IFN1 , 2001, The Journal of Immunology.
[46] S. Akira,et al. A Toll-like receptor recognizes bacterial DNA , 2000, Nature.
[47] D. Isenberg,et al. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. , 2000, Arthritis and rheumatism.
[48] J. Lord,et al. IFN-α and IFN-β: a link between immune memory and chronic inflammation , 2000 .
[49] J. Prieto,et al. Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy1 , 2000, The Journal of Immunology.
[50] Heriyanto,et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. , 2000, Vaccine.
[51] R. Purcell,et al. Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 , 2000, The Journal of Immunology.
[52] Gunther Hartmann,et al. Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells1 , 2000, The Journal of Immunology.
[53] D. Klinman,et al. Repeated Administration of Synthetic Oligodeoxynucleotides Expressing CpG Motifs Provides Long-Term Protection against Bacterial Infection , 1999, Infection and Immunity.
[54] S. Hoffman,et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. , 1999, Vaccine.
[55] L. Hültner,et al. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. , 1999, Journal of immunology.
[56] J. Finke,et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.
[57] A. Krieg,et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. , 1998, Journal of immunology.
[58] A. Krieg,et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.
[59] C. Harding,et al. CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.
[60] S. Agrawal,et al. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. , 1997, Antisense & nucleic acid drug development.
[61] G. Weiner,et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[62] C. Blank,et al. CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants , 1997, European journal of immunology.
[63] D. Richman,et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants , 1997, Nature Medicine.
[64] K. Heeg,et al. Bacterial DNA causes septic shock , 1997, Nature.
[65] D. Klinman,et al. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. , 1996, Journal of immunology.
[66] A. Krieg,et al. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. , 1996, Journal of immunology.
[67] A. Krieg,et al. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. , 1996, Journal of immunology.
[68] S. Beaucage,et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[69] G. Bishop,et al. CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.
[70] C. Surh,et al. T cell memory. , 2006, Current topics in microbiology and immunology.
[71] A. Krieg,et al. CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. , 2003, Journal of immunology.
[72] R. Coffman,et al. IMMUNOBIOLOGY: IL-10 Regulates Plasmacytoid Dendritic Cell Response to CpG Containing ImmunoStimulatory Sequences , 2003 .
[73] M. Crow. Interferon-alpha: a new target for therapy in systemic lupus erythematosus? , 2003, Arthritis and rheumatism.
[74] E. Silverman,et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. , 2003, Genomics.
[75] I. Kerr,et al. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. , 2003, Journal of immunology.
[76] A. Krieg,et al. CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.
[77] C. Janeway,et al. Innate immune recognition. , 2002, Annual review of immunology.
[78] C. Biron,et al. Innate immune responses to LCMV infections: natural killer cells and cytokines. , 2002, Current topics in microbiology and immunology.
[79] V. Hornung,et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. , 2001, European journal of immunology.
[80] V. Pascual,et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. , 2001, Science.
[81] J. Lord,et al. IFN-alpha and IFN-beta: a link between immune memory and chronic inflammation. , 2000, Immunology today.